Literature DB >> 10465246

Hypersensitivity myocarditis associated with ephedra use.

S M Zaacks1, L Klein, C D Tan, E R Rodriguez, J B Leikin.   

Abstract

BACKGROUND: Ephedrine has previously been described as a causative factor of vasculitis but myocarditis has not yet been associated with either ephedrine or its plant derivative ephedra. CASE REPORT: A 39-year-old African American male with hypertension presented to Rush Presbyterian St. Luke's Medical Center with a 1-month history of progressive dyspnea on exertion, orthopnea, and dependent edema. He was taking Ma Huang (Herbalife) 1-3 tablets twice daily for 3 months along with other vitamin supplements, pravastatin, and furosemide. Physical examination revealed a male in mild respiratory distress. The lung fields had rales at both bases without audible wheezes. Internal jugular venous pulsations were 5 cm above the sternal notch. Medical therapy with intravenous furosemide and oral enalapril was initiated upon admission. Cardiac catheterization with coronary angiography revealed normal coronary arteries, a dilated left ventricle, moderate pulmonary hypertension, and a pulmonary capillary wedge pressure of 34 mm Hg. The patient had right ventricular biopsy performed demonstrating mild myocyte hypertrophy and an infiltrate consisting predominantly of lymphocytes with eosinophils present in significantly increased numbers. Treatment for myocarditis was initiated with azothioprine 200 mg daily and prednisone 60 mg per day with a tapering course over 6 months. Anticoagulation with warfarin and diuretics was initiated and angiotensin-converting enzyme inhibition was continued. Hydralazine was added later. One month into therapy, an echocardiogram demonstrated improved left ventricular function with only mild global hypokinesis. A repeat right ventricular biopsy 2 months after the first admission showed no evidence of myocarditis. At 6 months, left ventricular ejection fraction was normal (EFN 50%) and the patient asymptomatic.
CONCLUSION: Ephedra (Ma Huang) is the suspected cause of hypersensitivity myocarditis in this patient due to the temporal course of disease and its propensity to induce vasculitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465246     DOI: 10.1081/clt-100102440

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  7 in total

1.  Coronary thrombosis related to use of Xenadrine RFA.

Authors:  Rajesh Sachdeva; Satish Sivasankaran; Robert F Fishman; Stuart W Zarich; Craig A McPherson
Journal:  Tex Heart Inst J       Date:  2005

2.  Ephedra and its application to sport performance: another concern for the athletic trainer?

Authors:  M E Powers
Journal:  J Athl Train       Date:  2001-10       Impact factor: 2.860

Review 3.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

4.  Uncharted waters: rare and unclassified cardiomyopathies characterized on cardiac magnetic resonance imaging.

Authors:  Ailbhe C O'Neill; Shaunagh McDermott; Carole A Ridge; Kenneth McDonald; David Keane; Jonathan D Dodd
Journal:  Insights Imaging       Date:  2010-10-19

5.  Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death.

Authors:  Natraj Katta; Sudarshan Balla; Kul Aggarwal
Journal:  Autops Case Rep       Date:  2016-12-30

6.  Identification and determination of synthetic pharmaceuticals as adulterants in eight common herbal weight loss supplements.

Authors:  Marjan Khazan; Mehdi Hedayati; Farzad Kobarfard; Sahar Askari; Fereidoun Azizi
Journal:  Iran Red Crescent Med J       Date:  2014-03-05       Impact factor: 0.611

Review 7.  Herbal bioactivation: the good, the bad and the ugly.

Authors:  Shufeng Zhou; Hwee-Ling Koh; Yihuai Gao; Zhi-yuan Gong; Edmund Jon Deoon Lee
Journal:  Life Sci       Date:  2004-01-09       Impact factor: 5.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.